Abstract 936P
Background
There are over 500,000 survivors of head and neck cancer (HNC) in the United States. While chronic pain is a common symptom across all cancer sites, we hypothesized it is more prevalent in HNC compared with other cancer sites, due to tumor location, treatment modality and functional impairment associated with HNC.
Methods
To compare self-reported chronic pain prevalence, we built a retrospective cohort of adult survivors with a history of cancer, using the National Health Interview Survey (NHIS) from 2010 to 2021. Study participants were grouped into HNC (n = 354) vs. other cancer survivors (n = 24,055), based on self-report of a previous cancer diagnosis. We estimated weighted prevalence rates of chronic pain in our sample, and in the final models, we estimated odds of reporting chronic pain while adjusting for sociodemographic (race, insurance, education, income, employment and smoking history) and clinical (depression, and self-rated health status) factors, using multivariate logistic regression analysis.
Results
Weighted, age-adjusted prevalence of chronic pain was significantly higher in HNC compared to other cancers (HNC = 45.5%, 95% CI: 42.6%, 48.5% vs. other cancers = 31.6%, 95% CI: 29.9%, 33.2%; p = 0.02). After adjusting for clinical and sociodemographic covariates, odds of reporting chronic pain remained significantly higher among HNC survivors compared to other cancers (aOR=1.34, 95% CI: 1.03, 1.75). Other factors associated with self-reported chronic pain included having depression (aOR=2.03, 95% CI: 1.90, 2.17), ≥ 65 years (aOR=0.74, 95% CI: 0.68, 0.80), being Hispanic (aOR=0.70, 95% CI:0.59, 0.83) compared to a non-Hispanic White, having private insurance (aOR=0.74, 95% CI: 0.69, 0.80), and education below high school level (aOR=1.39, 95% CI: 1.24, 1.56).
Conclusions
Chronic pain is highly prevalent among survivors of HNC, with almost 50% reporting chronic pain. Additionally, survivors of HNC are 34 percent more likely to report chronic pain compared to non-HNC survivors. Our findings highlight the burden of chronic pain in cancer, and the pressing need for effective pain management especially in HNC survivors.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1015P - The efficacy and mechanism of pan-FGFR inhibitor (AZD4547) combined with immunoagonists or immunosuppressants in FGFR-positive tumors
Presenter: Qizhi Ma
Session: Poster session 03
1016P - Phase I study of SOF10 plus atezolizumab in patients with advanced/recurrent solid tumours
Presenter: Toshihiko Doi
Session: Poster session 03
1017P - Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)
Presenter: Samuel Klempner
Session: Poster session 03
1018P - Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancer
Presenter: Omar Saavedra Santa Gadea
Session: Poster session 03
1019P - Bispecific PD1-IL2 antibody reshapes the inhibitory immune microenvironment of SMARCA4 mutant non-small cell lung cancer by reversing CD8+T cell exhaustion
Presenter: Bo Cheng
Session: Poster session 03
Resources:
Abstract
1020P - Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01
Presenter: Athanasia Dasargyri
Session: Poster session 03
1021P - Chemotherapy and hypomethylating agents enhance anti-tumor activity of PRAME ImmTAC
Presenter: Adel Benlahrech
Session: Poster session 03
1022P - A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Jonathan Riess
Session: Poster session 03
1023P - Long-term follow up of patients treated with a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancer
Presenter: Douglas McNeel
Session: Poster session 03
1024P - Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster session 03